P16INK4a hypermethylation and p53, p16 and MDM2 protein expression in Esophageal Squamous Cell Carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Taghavi, Noushin ^a,b   Biramijamal, Firouzeh ^a   Sotoudeh, Masoud ^b   Khademi, Hooman ^b   Malekzadeh, Reza ^b   Moaven, Omeed ^c   Memar, Bahram ^d   A'rabi, Azadeh ^c   Abbaszadegan, Mohammad R ^c  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRAN; MALE; MOLECULAR INTERACTION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR VOLUME; CHEMISTRY; CHI SQUARE DISTRIBUTION; CPG ISLAND; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IRAN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950675075     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-138     Document Type: Article

References (47)

1. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009, 20(3):556-563. 10.1093/annonc/mdn642, 19073863.
2. Mahboubi E, Kmet J, Cook PJ, Day NE, Ghadirian P, Salmasizadeh S. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer 1973, 28(3):197-214. 2008981, 4743904.
3. Islami F, Kamangar F, Aghcheli K, Fahimi S, Semnani S, Taghavi N, Marjani HA, Merat S, Nasseri-Moghaddam S, Pourshams A, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer 2004, 90(7):1402-1406. 10.1038/sj.bjc.6601737, 2409685, 15054463.
4. Kamangar F, Malekzadeh R, Dawsey SM, Saidi F. Esophageal cancer in Northeastern Iran: a review. Arch Iran Med 2007, 10(1):70-82.
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003, 349(23):2241-2252. 10.1056/NEJMra035010, 14657432.
6. Chen X, Yang CS. Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001, 22(8):1119-1129. 10.1093/carcin/22.8.1119, 11470739.
7. El-Rifai W, Powell SM. Molecular biology of gastric cancer. Semin Radiat Oncol 2002, 12(2):128-140. 10.1053/srao.2002.30815, 11979414.
8. Arora S, Mathew R, Mathur M, Chattopadhayay TK, Ralhan R. Alterations in MDM2 expression in esophageal squamous cell carcinoma: relationship with p53 status. Pathol Oncol Res 2001, 7(3):203-208. 10.1007/BF03032350, 11692147.
9. Tsuda H, Hashiguchi Y, Nishimura S, Kawamura N, Inoue T, Yamamoto K. Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. Gynecol Oncol 2003, 91(3):476-485. 10.1016/j.ygyno.2003.08.019, 14675665.
10. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996, 1287(2-3):77-102.
11. Dong M, Ma G, Tu W, Guo KJ, Tian YL, Dong YT. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol 2005, 11(14):2162-2165.
12. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA 2000, 97(21):11250-11255. 10.1073/pnas.210171597, 17186, 11016968.
13. Saito H, Tsujitani S, Oka S, Ikeguchi M, Maeta M, Kaibara N. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann Surg Oncol 2002, 9(5):450-456. 10.1007/BF02557267, 12052755.
14. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995, 147(3):545-560. 1870966, 7677168.
15. Jang SJ. [Cell cycle regulators as prognostic predictor of colorectal cancers]. Korean J Gastroenterol 2004, 44(6):346-349.
16. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054. 10.1056/NEJMra023075, 14627790.
17. Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006, 106(3):483-493. 10.1002/cncr.21657, 16362978.
18. Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene 2003, 22(42):6472-6478. 10.1038/sj.onc.1206955, 14528270.
19. Abbaszadegan MRAS, Raziee HR, Ghafarzadegan K, Ghavamnasiry MR. p16/INK4a promoter hypermethylation in serum, blood and tumor of patients with esophageal squamous cell carcinoma. IJBMS 2004, 6(4):6.
20. Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A'Rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaili-Shandiz E, et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol 2008, 14(13):2055-2060. 10.3748/wjg.14.2055, 2701527, 18395906.
21. Abbaszadegan MR, Raziee HR, Ghafarzadegan K, Shakeri MT, Afsharnezhad S, Ghavamnasiry MR. Aberrant p16 methylation, a possible epigenetic risk factor in familial esophageal squamous cell carcinoma. Int J Gastrointest Cancer 2005, 36(1):47-54. 10.1385/IJGC:36:1:047, 16227635.
22. Sepehr A, Taniere P, Martel-Planche G, Zia'ee AA, Rastgar-Jazii F, Yazdanbod M, Etemad-Moghadam G, Kamangar F, Saidi F, Hainaut P. Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran. Oncogene 2001, 20(50):7368-7374. 10.1038/sj.onc.1204912, 11704866.
23. Biramijamal F, Allameh A, Mirbod P, Groene HJ, Koomagi R, Hollstein M. Unusual profile and high prevalence of p53 mutations in esophageal squamous cell carcinomas from northern Iran. Cancer Res 2001, 61(7):3119-3123.
24. Taghavi NND, Merat S, Yazdanbod A, Hormazdi M, Sotoudeh MSS, Eslami F, Marjani HA, Fahimi S, Khademi H, Malekzadeh R. Epidemiology of upper gastrointestinal cancers in Iran: a sub site analysis of 761 cases. World J Gastroenterol 2007, 13(40):5367-5370.
25. Mathewa RAS, Khannaa R, Mathurb M, Shuklac NK, Ralhana R. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. European Journal of cancer 2002, 38(6):832-841. 10.1016/S0959-8049(02)00007-2, 11937319.
26. Zali MR, Moaven O, Asadzadeh Aghdaee H, Ghafarzadegan K, Jami Ahmadi K, Farzadnia K, Arabi A, MR A. Clinicopathological significance of E-cadherin, β-catenin and p53 expression in gastric adenocarinoma. JRMS 2009, 14(4):239-247.
27. Xing EP, Nie Y, Song Y, Yang GY, Cai YC, Wang LD, Yang CS. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999, 5(10):2704-2713.
28. Hardie LJ, Darnton SJ, Wallis YL, Chauhan A, Hainaut P, Wild CP, Casson AG. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 2005, 217(2):221-230. 10.1016/j.canlet.2004.06.025, 15617840.
29. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001, 7(10):3135-3138.
30. Wang J, Sasco AJ, Fu C, Xue H, Guo G, Hua Z, Zhou Q, Jiang Q, Xu B. Aberrant DNA methylation of P16, MGMT, and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17(1):118-125. 10.1158/1055-9965.EPI-07-0733, 18199718.
31. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002, 196(1):1-7. 10.1002/path.1024, 11748635.
32. Guan RJ, Fu Y, Holt PR, Pardee AB. Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 1999, 116(5):1063-1071. 10.1016/S0016-5085(99)70009-0, 10220498.
33. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 2003, 83(5):635-641.
34. Cui X, Wakai T, Shirai Y, Hatakeyama K, Hirano S. Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. Toxicol Sci 2006, 91(2):372-381. 10.1093/toxsci/kfj159, 16543296.
35. Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, Nelson HH, Kelsey KT. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006, 27(1):112-116. 10.1093/carcin/bgi172, 15987713.
36. Keyes MK, Jang H, Mason JB, Liu Z, Crott JW, Smith DE, Friso S, Choi SW. Older age and dietary folate are determinants of genomic and p16-specific DNA methylation in mouse colon. J Nutr 2007, 137(7):1713-1717.
37. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr 2007, 137(1 Suppl):223S-228S.
38. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999, 27(11):2291-2298. 10.1093/nar/27.11.2291, 148793, 10325416.
39. Van Zee KJ, Calvano JE, Bisogna M. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue. Oncogene 1998, 16(21):2723-2727. 10.1038/sj.onc.1201794, 9652738.
40. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, Yokota J, Hirohashi S. Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 1996, 24(3):575-579. 10.1002/hep.510240319, 8781327.
41. Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000, 80(5):689-695.
42. Shim YH, Park HJ, Choi MS, Kim JS, Kim H, Kim JJ, Jang JJ, Yu E. Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. Mod Pathol 2003, 16(5):430-436. 10.1097/01.MP.0000066799.99032.A7, 12748249.
43. Markl ID, Jones PA. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res 1998, 58(23):5348-5353.
44. Lee M, Sup Han W, Kyoung Kim O, Hee Sung S, Sun Cho M, Lee SN, Koo H. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract 2006, 202(6):415-424. 10.1016/j.prp.2005.11.011, 16675157.
45. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001, 19(2):299-304.
46. Ishii T, Murakami J, Notohara K, Cullings HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M, Shimizu K, et al. Oesophageal squamous cell carcinoma may develop within a background of accumulating DNA methylation in normal and dysplastic mucosa. Gut 2007, 56(1):13-19. 10.1136/gut.2005.089813, 1856655, 16785283.
47. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003, 4(6):351-358. 10.1016/S1470-2045(03)01115-X, 12788407.